GoAI
Get started
Precipio, Inc. logo

Precipio, Inc.

PRPO

NASDAQHealthcareMedical - Diagnostics & Research

Open in GoAI

Previous close

$30.45

+$1.02 · +3.47%

Aug 21, 4:00 PM ET

PRPO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

80

Undervalued

Momentum

50

Neutral

Sentiment

61

Bullish

Risk resilience

42

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
Ilan Danieli
Listed since
Jun 30, 2017
Employees
61

Market position

Day range

Current $30.45

52-week range

Current $30.45

Open
$29.48
Previous close
$29.43
Volume
69.65K
1.02× average
Average volume
68.35K
Average daily volume
Market cap
54.31M USD
Beta
1.29
Market reference 1
50-day average
$23.8147
+27.86% above average
200-day average
$24.693
+23.31% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-46.85×
P/B (TTM)
3.69×
P/S (TTM)
1.98×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
43.69%
Operating margin
-5.63%
Net margin
-4.42%

Financial health

Debt / equity
0.23×
Altman Z-score
-0.64
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends66%-8%-81%-154%Gross margin, FY2021: 27.03%Gross margin, FY2022: 26.67%Gross margin, FY2023: 39.60%Gross margin, FY2024: 47.35%Gross margin, FY2025: 44.52%Operating margin, FY2021: -108.63%Operating margin, FY2022: -135.96%Operating margin, FY2023: -50.14%Operating margin, FY2024: -26.41%Operating margin, FY2025: -5.00%Net margin, FY2021: -96.62%Net margin, FY2022: -129.65%Net margin, FY2023: -38.51%Net margin, FY2024: -26.87%Net margin, FY2025: -1.51%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 27.03%. Gross margin FY2022 26.67%. Gross margin FY2023 39.60%. Gross margin FY2024 47.35%. Gross margin FY2025 44.52%. Operating margin FY2021 -108.63%. Operating margin FY2022 -135.96%. Operating margin FY2023 -50.14%. Operating margin FY2024 -26.41%. Operating margin FY2025 -5.00%. Net margin FY2021 -96.62%. Net margin FY2022 -129.65%. Net margin FY2023 -38.51%. Net margin FY2024 -26.87%. Net margin FY2025 -1.51%.

Income trends

Revenue

24.05M USD+50.64%

Operating income

−1.2M USD+71.49%

Net income

−363K USD+91.54%
Income trends across reported periods27.73M USD13M USD−1.74M USD−16.48M USDRevenue, FY2021: 8.85M USDRevenue, FY2022: 9.41M USDRevenue, FY2023: 15.2M USDRevenue, FY2024: 15.97M USDRevenue, FY2025: 24.05M USDOperating income, FY2021: −9.61M USDOperating income, FY2022: −12.8M USDOperating income, FY2023: −7.62M USDOperating income, FY2024: −4.22M USDOperating income, FY2025: −1.2M USDNet income, FY2021: −8.55M USDNet income, FY2022: −12.2M USDNet income, FY2023: −5.85M USDNet income, FY2024: −4.29M USDNet income, FY2025: −363K USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 8.85M USD. Revenue FY2022 9.41M USD. Revenue FY2023 15.2M USD. Revenue FY2024 15.97M USD. Revenue FY2025 24.05M USD. Operating income FY2021 −9.61M USD. Operating income FY2022 −12.8M USD. Operating income FY2023 −7.62M USD. Operating income FY2024 −4.22M USD. Operating income FY2025 −1.2M USD. Net income FY2021 −8.55M USD. Net income FY2022 −12.2M USD. Net income FY2023 −5.85M USD. Net income FY2024 −4.29M USD. Net income FY2025 −363K USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue24.05M USD15.97M USD15.2M USD9.41M USD8.85M USD
Cost of goods sold13.34M USD8.41M USD9.18M USD6.9M USD6.46M USD
Gross profit10.71M USD7.56M USD6.02M USD2.51M USD2.39M USD
Research and development—2.3M USD2.7M USD2.7M USD2.3M USD
Selling, general, and administrative—11.78M USD13.64M USD15.31M USD12.01M USD
Operating expenses11.91M USD11.78M USD13.64M USD15.31M USD12.01M USD
Interest expense73K USD74K USD18K USD12K USD20K USD
Depreciation and amortization1.75M USD1.51M USD1.31M USD1.52M USD1.44M USD
Operating income−1.2M USD−4.22M USD−7.62M USD−12.8M USD−9.61M USD
Net income−363K USD−4.29M USD−5.85M USD−12.2M USD−8.55M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
22%
2 beats, 7 misses, 0 met estimates
Average EPS surprise
-250.07%
9 comparable reports
Latest EPS result
-0.12
Estimate -2 · Beat by 94.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.96-0.1-1.16-2.22Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26No estimateQ2 '26No estimateQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -0.23, estimate 0.74, surprise -131.08%, Miss. Q2 2025, reported May 14, 2025: actual -0.59, estimate 0.4, surprise -247.50%, Miss. Q3 2025, reported Aug 13, 2025: actual 0.05, estimate 0.74, surprise -93.24%, Miss. Q4 2025, reported Nov 14, 2025: actual -0.05, estimate 0.74, surprise -106.76%, Miss. Q1 2026, reported Mar 30, 2026: actual 0.33, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 18, 2026: actual -0.81, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual -0.12, estimate -2, surprise +94.00%, Beat. Q4 2026, reported Nov 16, 2026: actual —, estimate -2, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates8.52M6.15M3.79M1.42MQ1 '25EstimateQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26No estimateQ2 '26No estimateQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual —, estimate 8.01M USD, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual 4.26M USD, estimate 7.29M USD, surprise -41.64%, Miss. Q3 2025, reported Aug 13, 2025: actual 5.65M USD, estimate 8.01M USD, surprise -29.43%, Miss. Q4 2025, reported Nov 14, 2025: actual 6.77M USD, estimate 8.01M USD, surprise -15.54%, Miss. Q1 2026, reported Mar 30, 2026: actual 7.97M USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 18, 2026: actual 6.3M USD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual 7.02M USD, estimate 1.68M USD, surprise +319.16%, Beat. Q4 2026, reported Nov 16, 2026: actual —, estimate 1.68M USD, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Sep 22, 2023

1:20

Stock split

Effective Apr 29, 2019

1:15

Stock split

Effective Jun 13, 2017

1:30

Stock split

Effective Jan 28, 2014

1:12

PRPO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding PRPO

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
755.24K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24—
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
383.1K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53—
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
160.63K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39—
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
76.99K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95—
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
37.88K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02—
Dimensional - US Sustainability Core 1 ETF logoDimensional - US Sustainability Core 1 ETFDFSU
Market value
30.69K
Weight
0.00%
AUM
2.35B USD
Expense ratio
0.15%
Price / 1D
$48.20—
Dimensional - US Core Equity 2 ETF logoDimensional - US Core Equity 2 ETFDFAC
Market value
14.59K
Weight
0.00%
AUM
49.31B USD
Expense ratio
0.17%
Price / 1D
$45.61—
Dimensional - US Core Equity 1 ETF logoDimensional - US Core Equity 1 ETFDCOR
Market value
3.47K
Weight
0.00%
AUM
3.51B USD
Expense ratio
0.14%
Price / 1D
$84.54—

Continue in GoAI

Research PRPO

research.disclaimer